US 11,898,156 B2
Nano-vesicles derived from genus Morganella bacteria and use thereof
Yoon-Keun Kim, Paju-si (KR)
Assigned to MD HEALTHCARE INC., Seoul (KR)
Filed by MD HEALTHCARE INC., Seoul (KR)
Filed on Oct. 28, 2020, as Appl. No. 17/082,008.
Application 17/082,008 is a continuation of application No. 16/399,919, filed on Apr. 30, 2019, granted, now 10,858,670.
Application 16/399,919 is a continuation in part of application No. PCT/KR2018/016494, filed on Dec. 21, 2018.
Claims priority of application No. 10-2018-0004603 (KR), filed on Jan. 12, 2018; and application No. 10-2018-0158636 (KR), filed on Dec. 10, 2018.
Prior Publication US 2021/0054412 A1, Feb. 25, 2021
Int. Cl. C12N 15/88 (2006.01); C12Q 1/06 (2006.01); C12Q 1/686 (2018.01); C12Q 1/6886 (2018.01); A61K 9/127 (2006.01); A61K 35/74 (2015.01); C12N 1/20 (2006.01); C12Q 1/689 (2018.01); C12R 1/01 (2006.01)
CPC C12N 15/88 (2013.01) [A61K 9/1271 (2013.01); A61K 35/74 (2013.01); C12N 1/20 (2013.01); C12N 1/205 (2021.05); C12Q 1/06 (2013.01); C12Q 1/686 (2013.01); C12Q 1/689 (2013.01); C12Q 1/6886 (2013.01); C12R 2001/01 (2021.05)] 9 Claims
 
1. A method of reducing inflammation mediated by TNF-α or IL-6, the method comprising administering to a subject in need thereof a composition comprising an effective amount of vesicles derived from bacteria belonging to Morganella morganii, and thereby reducing inflammation mediated by TNF-α or IL-6, wherein the composition does not contain the cells of Morganella morganii.